1.14.11.29 Acute Kidney Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22262480&form=6&db=m Pre-ischemic Targeting of HIF Prolyl Hydroxylation Inhibits Fibrosis associated with Acute Kidney Injury. therapeutic application,unassigned 2,0 1.14.11.29 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9818031&form=6&db=m Induction of apoptosis in human pancreatic carcinoma cells by a synthetic bleomycin-like ligand. causal interaction,ongoing research,unassigned 3,2,0 1.14.11.29 Adenocarcinoma of Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30575913&form=6&db=m Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,4,0 1.14.11.29 Adenocarcinoma of Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33823854&form=6&db=m An integrative functional genomics approach reveals EGLN1 as a novel therapeutic target in KRAS mutated lung adenocarcinoma. causal interaction,therapeutic application,unassigned 2,4,0 1.14.11.29 Adenoma, Oxyphilic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18773095&form=6&db=m Somatic pairing of chromosome 19 in renal oncocytoma is associated with deregulated ELGN2-mediated oxygen-sensing response. unassigned - 1.14.11.29 Altitude Sickness http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22595196&form=6&db=m EPAS1 and EGLN1 associations with high altitude sickness in Han and Tibetan Chinese at the Qinghai-Tibetan Plateau. diagnostic usage,ongoing research,unassigned 2,2,0 1.14.11.29 Altitude Sickness http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25431923&form=6&db=m Variants of the low oxygen sensors EGLN1 and HIF-1AN associated with acute mountain sickness. unassigned - 1.14.11.29 Altitude Sickness http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31555147&form=6&db=m Population History and Altitude-Related Adaptation in the Sherpa. unassigned - 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20185832&form=6&db=m Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute ischemia-reperfusion injury. causal interaction,ongoing research,therapeutic application,unassigned 3,4,3,0 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20432181&form=6&db=m American chemical society - 239th national meeting - investigating new therapeutic candidates: part 2. causal interaction,therapeutic application,unassigned 1,4,0 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20973793&form=6&db=m New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein. causal interaction,therapeutic application,unassigned 4,4,0 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21406036&form=6&db=m HIF prolyl hydroxylase inhibitors for anemia. causal interaction,therapeutic application,unassigned 4,4,0 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22262480&form=6&db=m Pre-ischemic Targeting of HIF Prolyl Hydroxylation Inhibits Fibrosis associated with Acute Kidney Injury. therapeutic application,unassigned 2,0 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27438710&form=6&db=m A mechanistic link between renal ischemia and fibrosis. causal interaction,therapeutic application,unassigned 3,4,0 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28242135&form=6&db=m Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD. causal interaction,therapeutic application,unassigned 4,4,0 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28483447&form=6&db=m Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies. causal interaction,therapeutic application,unassigned 4,4,0 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28651951&form=6&db=m Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease. causal interaction,therapeutic application,unassigned 4,4,0 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29485740&form=6&db=m Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia. causal interaction,therapeutic application,unassigned 3,4,0 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29575006&form=6&db=m First-in-man / proof of concept study with molidustat - a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia. causal interaction,therapeutic application,unassigned 1,4,0 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29909605&form=6&db=m Anemia in conventional hemodialysis: Finding the optimal treatment balance. causal interaction,therapeutic application,unassigned 3,4,0 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30067604&form=6&db=m Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease. causal interaction,unassigned 3,0 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30952940&form=6&db=m Inhibition of prolyl hydroxylase domain (PHD) by JTZ-951 reduces obesity-related diseases in the liver, white adipose tissue, and kidney in mice with a high-fat diet. causal interaction,therapeutic application,unassigned 3,4,0 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30991411&form=6&db=m Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease. causal interaction,therapeutic application,unassigned 3,3,0 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31477256&form=6&db=m Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience. therapeutic application,unassigned 2,0 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31908020&form=6&db=m HIF hydroxylase inhibitors decrease cellular oxygen consumption depending on their selectivity. causal interaction,therapeutic application,unassigned 4,4,0 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31919558&form=6&db=m Effects of oral iron and calcium supplement on the pharmacokinetics and pharmacodynamics of molidustat: an oral HIF-PH inhibitor for the treatment of renal anaemia. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,2,4 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31996409&form=6&db=m Prolyl Hydroxylase Domain Inhibitor Protects against Metabolic Disorders and Associated Kidney Disease in Obese Type 2 Diabetic Mice. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32016052&form=6&db=m Prolyl hydroxylase domain inhibitors: a new era in the management of renal anemia. unassigned - 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32309288&form=6&db=m Treatment of Renal Anemia with Roxadustat: Advantages and Achievement. causal interaction,unassigned 2,0 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32476498&form=6&db=m Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease? causal interaction,therapeutic application,unassigned 3,4,0 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32487538&form=6&db=m Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease. causal interaction,ongoing research,therapeutic application,unassigned 2,1,4,0 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32676148&form=6&db=m Pyrazolo[4,3-d]pyrimidine Derivatives as a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Domain Inhibitor for the Treatment of Anemia. unassigned - 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33222343&form=6&db=m Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors. therapeutic application,unassigned 4,0 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33628028&form=6&db=m Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease. causal interaction,therapeutic application,unassigned 4,4,0 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33670704&form=6&db=m ESA, Iron Therapy and New Drugs: Are There New Perspectives in the Treatment of Anaemia? causal interaction,therapeutic application,unassigned 3,4,0 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33743638&form=6&db=m Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis. therapeutic application,unassigned 4,0 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33777493&form=6&db=m Treatment of anemia in difficult-to-manage patients with chronic kidney disease. causal interaction,therapeutic application,unassigned 3,4,0 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34143801&form=6&db=m Hypoxia-inducible factor prolyl hydroxylase domain inhibitor may maintain hemoglobin synthesis at lower serum ferritin and transferrin saturation levels than darbepoetin alfa. causal interaction,therapeutic application,unassigned 3,2,0 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34280923&form=6&db=m Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents. causal interaction,therapeutic application,unassigned 3,4,0 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34339435&form=6&db=m A small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase improves obesity, nephropathy and cardiomyopathy in obese ZSF1 rats. causal interaction,therapeutic application,unassigned 2,4,0 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34442028&form=6&db=m Novel Iron Parameters in Patients with Type 2 Diabetes Mellitus in Relation to Kidney Function. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 1.14.11.29 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34497234&form=6&db=m [Future perspectives of treatment for anemia in chronic kidney disease (CKD) using hypoxia-inducible factor prolyl hydroxylase inhibitors]. therapeutic application,unassigned 4,0 1.14.11.29 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25260610&form=6&db=m Circulating tetrahydrobiopterin as a novel biomarker for abdominal aortic aneurysm. unassigned - 1.14.11.29 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22083158&form=6&db=m Role of uncoupled endothelial nitric oxide synthase in abdominal aortic aneurysm formation: treatment with folic acid. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,1,4 1.14.11.29 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24256203&form=6&db=m Suppression of abdominal aortic aneurysm formation by inhibition of prolyl hydroxylase domain protein through attenuation of inflammation and extracellular matrix disruption. causal interaction,ongoing research,unassigned 1,2,0 1.14.11.29 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24558445&form=6&db=m Recoupling of eNOS with folic acid prevents abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E null mice. ongoing research,therapeutic application,unassigned 2,3,0 1.14.11.29 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27125949&form=6&db=m Deficiency of the oxygen sensor prolyl hydroxylase 1 attenuates hypercholesterolaemia, atherosclerosis, and hyperglycaemia. causal interaction,ongoing research,unassigned 4,2,0 1.14.11.29 Autoimmune Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20432181&form=6&db=m American chemical society - 239th national meeting - investigating new therapeutic candidates: part 2. causal interaction,therapeutic application,unassigned 1,4,0 1.14.11.29 Bone Resorption http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28418093&form=6&db=m Hypoxia-inducible factor 1-alpha does not regulate osteoclastogenesis but enhances bone resorption activity via prolyl-4-hydroxylase 2. unassigned - 1.14.11.29 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22933585&form=6&db=m Neuron-Specific Prolyl-4-Hydroxylase Domain 2 Knockout Reduces Brain Injury After Transient Cerebral Ischemia. causal interaction,unassigned 1,0 1.14.11.29 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19878873&form=6&db=m Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 1.14.11.29 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20727020&form=6&db=m DNA methylation analysis of the HIF-1? prolyl hydroxylase domain genes PHD1, PHD2, PHD3 and the factor inhibiting HIF gene FIH in invasive breast carcinomas. ongoing research,unassigned 1,0 1.14.11.29 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23225569&form=6&db=m Knockdown of prolyl-4-hydroxylase domain 2 inhibits tumor growth of human breast cancer MDA-MB-231 cells by affecting TGF-?1 processing. causal interaction,ongoing research,therapeutic application,unassigned 1,4,1,0 1.14.11.29 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25052766&form=6&db=m Hypoxia represses microRNA biogenesis proteins in breast cancer cells. diagnostic usage,ongoing research,unassigned 1,3,0 1.14.11.29 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26430873&form=6&db=m Targeting MCM2 function as a novel strategy for the treatment of highly malignant breast tumors. ongoing research,therapeutic application,unassigned 3,1,0 1.14.11.29 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26492917&form=6&db=m EglN2 associates with the NRF1-PGC1? complex and controls mitochondrial function in breast cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,1 1.14.11.29 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27308620&form=6&db=m EglN2 positively regulates mitochondrial function in breast cancer. therapeutic application,unassigned 2,0 1.14.11.29 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27368101&form=6&db=m Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine. ongoing research,unassigned 1,0 1.14.11.29 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28036276&form=6&db=m EglN2 contributes to triple negative breast tumorigenesis by functioning as a substrate for the FBW7 tumor suppressor. ongoing research,therapeutic application,unassigned 4,1,0 1.14.11.29 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28038470&form=6&db=m Hypoxia-inducible factor prolyl hydroxylase 2 (PHD2) is a direct regulator of epidermal growth factor receptor (EGFR) signaling in breast cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,2,0 1.14.11.29 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29693343&form=6&db=m Detection of a 4-bp Insertion/deletion Polymorphism within the Promoter of EGLN2 Using Mismatch PCR-RFLP and Its Association with Susceptibility to Breast Cancer diagnostic usage,ongoing research,unassigned 3,3,0 1.14.11.29 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31729379&form=6&db=m Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer. unassigned - 1.14.11.29 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32558530&form=6&db=m Long non-coding RNA LINC00662 promotes proliferation and migration of breast cancer cells via regulating the miR-497-5p/EglN2 axis. causal interaction,unassigned 4,0 1.14.11.29 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19878865&form=6&db=m Edging toward new therapeutics with cyclin D1 Egl'ng on cancer. ongoing research,unassigned 1,0 1.14.11.29 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19878873&form=6&db=m Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 1.14.11.29 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20460169&form=6&db=m Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells. ongoing research,unassigned 1,0 1.14.11.29 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22014577&form=6&db=m Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. causal interaction,therapeutic application,unassigned 4,1,0 1.14.11.29 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22236543&form=6&db=m Prolyl hydroxylase domain 2 protein is a strong prognostic marker in human gastric cancer. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,2,0 1.14.11.29 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25982285&form=6&db=m Association of chromosome 19 to lung cancer genotypes and phenotypes. causal interaction,therapeutic application,unassigned 3,1,0 1.14.11.29 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26492917&form=6&db=m EglN2 associates with the NRF1-PGC1? complex and controls mitochondrial function in breast cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,1 1.14.11.29 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27308620&form=6&db=m EglN2 positively regulates mitochondrial function in breast cancer. therapeutic application,unassigned 2,0 1.14.11.29 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28036276&form=6&db=m EglN2 contributes to triple negative breast tumorigenesis by functioning as a substrate for the FBW7 tumor suppressor. ongoing research,therapeutic application,unassigned 4,1,0 1.14.11.29 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9818031&form=6&db=m Induction of apoptosis in human pancreatic carcinoma cells by a synthetic bleomycin-like ligand. causal interaction,ongoing research,unassigned 3,2,0 1.14.11.29 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23026137&form=6&db=m An insertion/deletion polymorphism within RERT-lncRNA modulates hepatocellular carcinoma risk. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,3,0 1.14.11.29 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24477694&form=6&db=m Hypoxia-inducible factor (HIF)-independent expression mechanism and novel function of HIF prolyl hydroxylase-3 in renal cell carcinoma. causal interaction,ongoing research,unassigned 1,3,0 1.14.11.29 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30575913&form=6&db=m Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,4,0 1.14.11.29 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30950543&form=6&db=m Activation of prolyl hydroxylase-2 for stabilization of mitochondrial stress along with simultaneous downregulation of HIF-1?/FASN in ER + breast cancer subtype. causal interaction,diagnostic usage,unassigned 2,3,0 1.14.11.29 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33118406&form=6&db=m Decreased prolyl hydroxylase 3 mRNA expression in oncocytomas compared with clear cell renal cell carcinoma. causal interaction,ongoing research,unassigned 3,3,0 1.14.11.29 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34090331&form=6&db=m Effect of Voacamine upon inhibition of hypoxia induced fatty acid synthesis in a rat model of methyln-nitrosourea induced mammary gland carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,1,2,1 1.14.11.29 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25232407&form=6&db=m Effect of stable transfection with PHD3 on growth and proliferation of HepG2 cells in vitro and in vivo. ongoing research,unassigned 4,0 1.14.11.29 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28099905&form=6&db=m Prolyl hydroxylase domain protein 3 and asparaginyl hydroxylase factor inhibiting HIF-1 levels are predictive of tumoral behavior and prognosis in hepatocellular carcinoma. causal interaction,diagnostic usage,unassigned 1,2,0 1.14.11.29 Carcinoma, Non-Small-Cell Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21748337&form=6&db=m The expression of prolyl hydroxylase domain enzymes are up-regulated and negatively correlated with Bcl-2 in non-small cell lung cancer. causal interaction,diagnostic usage,unassigned 3,3,0 1.14.11.29 Carcinoma, Renal Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19159641&form=6&db=m iTRAQ proteomic identification of pVHL-dependent and -independent targets of Egln1 prolyl hydroxylase knockdown in renal carcinoma cells. causal interaction,unassigned 1,0 1.14.11.29 Carcinoma, Renal Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24477694&form=6&db=m Hypoxia-inducible factor (HIF)-independent expression mechanism and novel function of HIF prolyl hydroxylase-3 in renal cell carcinoma. causal interaction,ongoing research,unassigned 1,3,0 1.14.11.29 Carcinoma, Renal Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33118406&form=6&db=m Decreased prolyl hydroxylase 3 mRNA expression in oncocytomas compared with clear cell renal cell carcinoma. causal interaction,ongoing research,unassigned 3,3,0 1.14.11.29 Carcinoma, Squamous Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30575913&form=6&db=m Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,4,0 1.14.11.29 Choroidal Neovascularization http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28186209&form=6&db=m Gene Transfer of Prolyl Hydroxylase Domain 2 Inhibits Hypoxia-inducible Angiogenesis in a Model of Choroidal Neovascularization. ongoing research,unassigned 2,0 1.14.11.29 Chronic Limb-Threatening Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24105925&form=6&db=m HIF-prolyl hydroxylase 2 inhibition enhances the efficiency of mesenchymal stem cells-based therapies for the treatment of critical limb ischemia. therapeutic application,unassigned 4,0 1.14.11.29 Colitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18026919&form=6&db=m Hypoxia and gastrointestinal disease. therapeutic application,unassigned 4,0 1.14.11.29 Colitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20600011&form=6&db=m Loss of Prolyl Hydroxylase-1 Protects Against Colitis Through Reduced Epithelial Cell Apoptosis and Increased Barrier Function. causal interaction,ongoing research,therapeutic application,unassigned 3,3,2,0 1.14.11.29 Colitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24361888&form=6&db=m N-(2-Mercaptopropionyl)-glycine, a diffusible antioxidant, activates HIF-1 by inhibiting HIF prolyl hydroxylase-2: implication in amelioration of rat colitis by the antioxidant. causal interaction,ongoing research,unassigned 3,3,0 1.14.11.29 Colitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24493931&form=6&db=m Therapeutic treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates murine colitis. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 1.14.11.29 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28218358&form=6&db=m An insertion/deletion polymorphism within the promoter of EGLN2 is associated with susceptibility to colorectal cancer. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,2,0 1.14.11.29 Dystonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8764604&form=6&db=m Tetrahydrobiopterin and biogenic amine metabolism in the hph-1 mouse. causal interaction,unassigned 1,0 1.14.11.29 Dystonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15234340&form=6&db=m Congenic mapping and genotyping of the tetrahydrobiopterin-deficient hph-1 mouse. ongoing research,therapeutic application,unassigned 1,2,0 1.14.11.29 Dystonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15530890&form=6&db=m Alterations in expression of dopamine receptors and neuropeptides in the striatum of GTP cyclohydrolase-deficient mice. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,2,1 1.14.11.29 Dystonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29913682&form=6&db=m GCH1 variants, tetrahydrobiopterin and their effects on pain sensitivity. ongoing research,therapeutic application,unassigned 2,1,0 1.14.11.29 Endometrial Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16161047&form=6&db=m Induction of human endometrial cancer cell senescence through modulation of HIF-1alpha activity by EGLN1. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 1.14.11.29 Escherichia coli Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31841391&form=6&db=m Acidosis induces antimicrobial peptide expression and resistance to uropathogenic E. coli infection in kidney collecting duct cells via HIF-1?. therapeutic application,unassigned 2,0 1.14.11.29 Gastroparesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25714576&form=6&db=m In vivo ultrasound assessment of gastric emptying in newborn mice. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,1,0 1.14.11.29 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25010988&form=6&db=m Prolyl-4-hydroxylase 2 enhances hypoxia-induced glioblastoma cell death by regulating the gene expression of hypoxia-inducible factor-?. ongoing research,unassigned 3,0 1.14.11.29 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18600258&form=6&db=m Enhanced delivery efficiency of recombinant adenovirus into tumor and mesenchymal stem cells by a novel PTD. ongoing research,unassigned 1,0 1.14.11.29 Glucose Intolerance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28469071&form=6&db=m Tetrahydrobiopterin activates brown adipose tissue and regulates systemic energy metabolism. ongoing research,therapeutic application,unassigned 4,2,0 1.14.11.29 gtp cyclohydrolase i deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7542713&form=6&db=m Tetrahydrobiopterin deficiency and brain nitric oxide synthase in the hph1 mouse. causal interaction,ongoing research,unassigned 3,4,0 1.14.11.29 gtp cyclohydrolase i deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19286659&form=6&db=m GTP cyclohydrolase I expression, protein, and activity determine intracellular tetrahydrobiopterin levels, independent of GTP cyclohydrolase feedback regulatory protein expression. ongoing research,unassigned 4,0 1.14.11.29 Heart Defects, Congenital http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30906831&form=6&db=m An EGLN1 mutation may regulate hypoxic response in cyanotic congenital heart disease through the PHD2/HIF-1A pathway. causal interaction,unassigned 3,0 1.14.11.29 Herpes Simplex http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17981031&form=6&db=m Antiviral activities against herpes simplex virus type 1 by HPH derivatives and their structure-activity relationships. ongoing research,unassigned 4,0 1.14.11.29 Hyperemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32980388&form=6&db=m GTP-cyclohydrolase deficiency induced peripheral and deep microcirculation dysfunction with age. ongoing research,therapeutic application,unassigned 1,1,0 1.14.11.29 Hyperglycemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29228603&form=6&db=m Elevating VEGF-A and PDGF-BB secretion by salidroside enhances neoangiogenesis in diabetic hind-limb ischemia. causal interaction,ongoing research,unassigned 1,2,0 1.14.11.29 Hyperglycemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30659610&form=6&db=m ROS- and HIF1?-dependent IGFBP3 upregulation blocks IGF1 survival signaling and thereby mediates high-glucose-induced cardiomyocyte apoptosis. causal interaction,therapeutic application,unassigned 2,1,0 1.14.11.29 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33370224&form=6&db=m Erythrocytosis: genes and pathways involved in disease development. unassigned - 1.14.11.29 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15824199&form=6&db=m Pulmonary hypertension in a GTP-cyclohydrolase 1-deficient mouse. causal interaction,ongoing research,unassigned 4,2,0 1.14.11.29 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21059996&form=6&db=m GTP cyclohydrolase I/BH4 pathway protects EPCs via suppressing oxidative stress and thrombospondin-1 in salt-sensitive hypertension. causal interaction,therapeutic application,unassigned 3,1,0 1.14.11.29 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22083158&form=6&db=m Role of uncoupled endothelial nitric oxide synthase in abdominal aortic aneurysm formation: treatment with folic acid. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,1,4 1.14.11.29 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27596558&form=6&db=m [Correlation between EGLN1 gene, protein express in lung tissue of rats and pulmonary artery pressure at different altitude]. diagnostic usage,ongoing research,unassigned 4,3,0 1.14.11.29 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15824200&form=6&db=m Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension. causal interaction,ongoing research,therapeutic application,unassigned 3,2,1,0 1.14.11.29 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21982896&form=6&db=m Pulmonary hypertension in the newborn GTP cyclohydrolase I-deficient mouse. causal interaction,therapeutic application,unassigned 3,1,0 1.14.11.29 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30339838&form=6&db=m Prolyl Hydroxylase Domain-2 Protein Regulates Lipopolysaccharide-Induced Vascular Inflammation. causal interaction,unassigned 3,0 1.14.11.29 hypoxia-inducible factor-proline dioxygenase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27720797&form=6&db=m Neuronal prolyl-4-hydroxylase 2 deficiency improves cognitive abilities in a murine model of cerebral hypoperfusion. therapeutic application,unassigned 1,0 1.14.11.29 hypoxia-inducible factor-proline dioxygenase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29151278&form=6&db=m Tetrahydrobiopterin (BH ongoing research,unassigned 1,0 1.14.11.29 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31841391&form=6&db=m Acidosis induces antimicrobial peptide expression and resistance to uropathogenic E. coli infection in kidney collecting duct cells via HIF-1?. therapeutic application,unassigned 2,0 1.14.11.29 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32839523&form=6&db=m Hypoxic gene expression in chronic hepatitis B virus infected patients is not observed in state-of-the-art in vitro and mouse infection models. causal interaction,ongoing research,unassigned 3,3,0 1.14.11.29 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28469071&form=6&db=m Tetrahydrobiopterin activates brown adipose tissue and regulates systemic energy metabolism. ongoing research,therapeutic application,unassigned 4,2,0 1.14.11.29 Intellectual Disability http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33298456&form=6&db=m Transmembrane Prolyl 4-Hydroxylase is a Novel Regulator of Calcium Signaling in Astrocytes. causal interaction,unassigned 4,0 1.14.11.29 Ischemic Attack, Transient http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22933585&form=6&db=m Neuron-Specific Prolyl-4-Hydroxylase Domain 2 Knockout Reduces Brain Injury After Transient Cerebral Ischemia. causal interaction,unassigned 1,0 1.14.11.29 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27001147&form=6&db=m Neuronal deficiency of HIF prolyl 4-hydroxylase 2 in mice improves ischemic stroke recovery in an HIF dependent manner. causal interaction,therapeutic application,unassigned 4,1,0 1.14.11.29 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30677555&form=6&db=m HIF-prolyl hydroxylase 2 silencing using siRNA delivered by MRI-visible nanoparticles improves therapy efficacy of transplanted EPCs for ischemic stroke. causal interaction,therapeutic application,unassigned 3,4,0 1.14.11.29 Kidney Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22875277&form=6&db=m ?-Ketoglutarate-related inhibitors of HIF prolyl hydroxylases are substrates of renal organic anion transporters 1 (OAT1) and 4 (OAT4). unassigned - 1.14.11.29 Kidney Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27155083&form=6&db=m Inhibitors of oxygen sensing prolyl hydroxylases regulate nuclear localization of the transcription factors Smad2 and YAP/TAZ involved in CTGF synthesis. therapeutic application,unassigned 1,0 1.14.11.29 Kidney Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31996409&form=6&db=m Prolyl Hydroxylase Domain Inhibitor Protects against Metabolic Disorders and Associated Kidney Disease in Obese Type 2 Diabetic Mice. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 1.14.11.29 Kidney Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34339435&form=6&db=m A small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase improves obesity, nephropathy and cardiomyopathy in obese ZSF1 rats. causal interaction,therapeutic application,unassigned 2,4,0 1.14.11.29 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30036883&form=6&db=m Regulatory Role of Endothelial PHD2 in the Hepatic Steatosis. causal interaction,unassigned 1,0 1.14.11.29 Liver Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22420978&form=6&db=m Effect of prolyl hydroxylase domain-2 haplodeficiency on the hepatocarcinogenesis in mice. causal interaction,therapeutic application,unassigned 3,1,0 1.14.11.29 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21748337&form=6&db=m The expression of prolyl hydroxylase domain enzymes are up-regulated and negatively correlated with Bcl-2 in non-small cell lung cancer. causal interaction,diagnostic usage,unassigned 3,3,0 1.14.11.29 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24045616&form=6&db=m Variants in two adjacent genes, EGLN2 and CYP2A6, influence smoking behavior related to disease risk via different mechanisms. causal interaction,unassigned 2,0 1.14.11.29 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30073577&form=6&db=m Correlations of an Insertion/Deletion Polymorphism (rs10680577) in the RERT-lncRNA with the Susceptibility, Clinicopathological Features, and Prognosis of Lung Cancer. diagnostic usage,unassigned 4,0 1.14.11.29 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34065840&form=6&db=m Gene Expression Levels of the Prolyl Hydroxylase Domain Proteins PHD1 and PHD2 but Not PHD3 Are Decreased in Primary Tumours and Correlate with Poor Prognosis of Patients with Surgically Resected Non-Small-Cell Lung Cancer. diagnostic usage,unassigned 2,0 1.14.11.29 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34164477&form=6&db=m The predictive prognostic values of CBFA2T3, STX3, DENR, EGLN1, FUT4, and PCDH7 in lung cancer. diagnostic usage,unassigned 3,0 1.14.11.29 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19147576&form=6&db=m Melanoma antigen-11 inhibits the hypoxia-inducible factor prolyl hydroxylase 2 and activates hypoxic response. therapeutic application,unassigned 2,0 1.14.11.29 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20574527&form=6&db=m Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1alpha in melanoma cells. ongoing research,unassigned 2,0 1.14.11.29 Mitochondrial Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34285383&form=6&db=m Biallelic P4HTM variants associated with HIDEA syndrome and mitochondrial respiratory chain complex I deficiency. causal interaction,unassigned 3,0 1.14.11.29 Monoclonal Gammopathy of Undetermined Significance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19737309&form=6&db=m The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 1.14.11.29 Mouth Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32464411&form=6&db=m Hypoxia responsiveness linked variant in EGLN1 gene is enriched in oral cancer patients. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,4,1 1.14.11.29 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19737309&form=6&db=m The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 1.14.11.29 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23978105&form=6&db=m Targeted Gene deletion of Prolyl Hydroxylase Domain Protein 3 Triggers Angiogenesis And Preserves Cardiac Function by stabilizing Hypoxia inducible Factor 1 Alpha Following Myocardial Infarction. causal interaction,ongoing research,therapeutic application,unassigned 1,2,2,0 1.14.11.29 Nasopharyngeal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19628018&form=6&db=m Identification and characterization of the hypoxia-responsive element in human stanniocalcin-1 gene. ongoing research,unassigned 3,0 1.14.11.29 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23055435&form=6&db=m Hypoxia-inducible factors as key regulators of tumor inflammation. causal interaction,therapeutic application,unassigned 3,2,0 1.14.11.29 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23077544&form=6&db=m Thermal unfolding pathway of PHD2 catalytic domain in three different PHD2 species: computational approaches. causal interaction,therapeutic application,unassigned 3,1,0 1.14.11.29 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23913502&form=6&db=m Loss of prolyl hydroxylase-2 in myeloid cells and T-lymphocytes impairs tumor development. causal interaction,ongoing research,unassigned 3,2,0 1.14.11.29 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24618895&form=6&db=m Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,1,0 1.14.11.29 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32905516&form=6&db=m Overexpression of hydroxyproline via EGLN/HIF1A is associated with distant metastasis in pancreatic cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15328163&form=6&db=m Induction of plasminogen activator inhibitor I gene expression by intracellular calcium via hypoxia-inducible factor-1. unassigned - 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16096374&form=6&db=m Regulation of HIF by prolyl hydroxylases: recruitment of the candidate tumor suppressor protein ING4. unassigned - 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16161047&form=6&db=m Induction of human endometrial cancer cell senescence through modulation of HIF-1alpha activity by EGLN1. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18927305&form=6&db=m Overexpression of the Oxygen Sensors PHD-1, PHD-2, PHD-3, and FIH Is Associated with Tumor Aggressiveness in Pancreatic Endocrine Tumors. causal interaction,diagnostic usage,unassigned 3,3,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19092153&form=6&db=m PHD2 mutation and congenital erythrocytosis with paraganglioma. causal interaction,unassigned 4,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19737309&form=6&db=m The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19878865&form=6&db=m Edging toward new therapeutics with cyclin D1 Egl'ng on cancer. ongoing research,unassigned 1,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19878873&form=6&db=m Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20034026&form=6&db=m Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression. causal interaction,ongoing research,therapeutic application,unassigned 3,3,3,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20178464&form=6&db=m The role of HIF prolyl hydroxylases in tumor growth. causal interaction,ongoing research,unassigned 3,1,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20383689&form=6&db=m HIF prolyl hydroxylase-3 mediates alpha-ketoglutarate-induced apoptosis and tumor suppression. therapeutic application,unassigned 1,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20973793&form=6&db=m New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein. causal interaction,therapeutic application,unassigned 4,4,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21275967&form=6&db=m Analysis of the oxygen sensing pathway genes in familial chronic myeloproliferative neoplasms and identification of a novel EGLN1 germ-line mutation. causal interaction,unassigned 2,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21436457&form=6&db=m Inhibition of HIF Prolyl Hydroxylase-2 Blocks Tumor Growth in Mice through the Anti-Proliferative Activity of Transforming Growth Factor{beta} ongoing research,unassigned 3,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21796619&form=6&db=m Identification of a novel recurrent 1q42.2-1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas. unassigned - 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21933857&form=6&db=m Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia. causal interaction,unassigned 3,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22236543&form=6&db=m Prolyl hydroxylase domain 2 protein is a strong prognostic marker in human gastric cancer. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,2,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22354010&form=6&db=m HIF prolyl hydroxylase-2 inhibition diminishes tumor growth through matrix metalloproteinase-induced TGF? activation. causal interaction,ongoing research,unassigned 3,1,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22420978&form=6&db=m Effect of prolyl hydroxylase domain-2 haplodeficiency on the hepatocarcinogenesis in mice. causal interaction,therapeutic application,unassigned 3,1,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22842216&form=6&db=m Exposure to cigarette smoke induces overexpression of von Hippel-Lindau tumor suppressor in mouse skeletal muscle. causal interaction,ongoing research,unassigned 2,2,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22897845&form=6&db=m A New Role for PHD in Chemotherapy. ongoing research,unassigned 3,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23026137&form=6&db=m An insertion/deletion polymorphism within RERT-lncRNA modulates hepatocellular carcinoma risk. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,3,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23055435&form=6&db=m Hypoxia-inducible factors as key regulators of tumor inflammation. causal interaction,therapeutic application,unassigned 3,2,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23225569&form=6&db=m Knockdown of prolyl-4-hydroxylase domain 2 inhibits tumor growth of human breast cancer MDA-MB-231 cells by affecting TGF-?1 processing. causal interaction,ongoing research,therapeutic application,unassigned 1,4,1,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23487784&form=6&db=m Estrogen receptor ? sustains epithelial differentiation by regulating prolyl hydroxylase 2 transcription. causal interaction,unassigned 3,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23913502&form=6&db=m Loss of prolyl hydroxylase-2 in myeloid cells and T-lymphocytes impairs tumor development. causal interaction,ongoing research,unassigned 3,2,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24145445&form=6&db=m Regulation of IL-1?-induced NF-?B by hydroxylases links key hypoxic and inflammatory signaling pathways. diagnostic usage,therapeutic application,unassigned 3,1,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24149047&form=6&db=m The VHL gene is epigenetically inactivated in pheochromocytomas and abdominal paragangliomas. unassigned - 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24220244&form=6&db=m Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. ongoing research,unassigned 4,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24618895&form=6&db=m Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,1,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24694336&form=6&db=m Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma. causal interaction,unassigned 2,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24899893&form=6&db=m Paragangliomas/Pheochromocytomas: clinically oriented genetic testing. unassigned - 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25232407&form=6&db=m Effect of stable transfection with PHD3 on growth and proliferation of HepG2 cells in vitro and in vivo. ongoing research,unassigned 4,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26430873&form=6&db=m Targeting MCM2 function as a novel strategy for the treatment of highly malignant breast tumors. ongoing research,therapeutic application,unassigned 3,1,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27307407&form=6&db=m Prolyl hydroxylase-2 inhibits liver tumor cell proliferation and cyclin D1 expression in a hydroxylase-dependent manner. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,3 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27702652&form=6&db=m Prolyl hydroxylase domain enzymes and their role in cell signaling and cancer metabolism. causal interaction,ongoing research,unassigned 1,4,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27774472&form=6&db=m Prolyl hydroxylase domain enzymes: important regulators of cancer metabolism. diagnostic usage,therapeutic application,unassigned 1,1,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28036276&form=6&db=m EglN2 contributes to triple negative breast tumorigenesis by functioning as a substrate for the FBW7 tumor suppressor. ongoing research,therapeutic application,unassigned 4,1,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28089830&form=6&db=m Tumor suppressor SPOP ubiquitinates and degrades EglN2 to compromise growth of prostate cancer cells. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28231563&form=6&db=m Hypoxia Pathway Mutations in Pheochromocytomas and Paragangliomas. causal interaction,unassigned 3,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28790514&form=6&db=m The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer. causal interaction,unassigned 4,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30073577&form=6&db=m Correlations of an Insertion/Deletion Polymorphism (rs10680577) in the RERT-lncRNA with the Susceptibility, Clinicopathological Features, and Prognosis of Lung Cancer. diagnostic usage,unassigned 4,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30083155&form=6&db=m Hypoxia Exacerbates Inflammatory Acute Lung Injury via the Toll-Like Receptor 4 Signaling Pathway. unassigned - 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30575913&form=6&db=m Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,4,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30665327&form=6&db=m EGLN2 DNA methylation and expression interact with HIF1A to affect survival of early-stage NSCLC. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,2,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30817904&form=6&db=m The roles and signaling pathways of prolyl-4-hydroxylase 2 in the tumor microenvironment. causal interaction,unassigned 2,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30898838&form=6&db=m Genome-Wide Interrogation of Human Cancers Identifies EGLN1 Dependency in Clear Cell Ovarian Cancers. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30948450&form=6&db=m Genome-wide Analysis of Common Copy Number Variation and Epithelial Ovarian Cancer Risk. causal interaction,diagnostic usage,ongoing research,unassigned 3,1,3,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30950543&form=6&db=m Activation of prolyl hydroxylase-2 for stabilization of mitochondrial stress along with simultaneous downregulation of HIF-1?/FASN in ER + breast cancer subtype. causal interaction,diagnostic usage,unassigned 2,3,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31355331&form=6&db=m Clockophagy is a novel selective autophagy process favoring ferroptosis. causal interaction,therapeutic application,unassigned 2,1,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31414584&form=6&db=m Association between an indel polymorphism within the distal promoter of EGLN2 and cancer risk: An updated meta-analysis. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31788113&form=6&db=m Identification of hub genes and key pathways associated with the progression of gynecological cancer. therapeutic application,unassigned 1,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32458625&form=6&db=m Association of EGLN2 rs10680577 Polymorphism with the Risk and Clinicopathological Features of Patients with Prostate Cancer. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,1,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33118406&form=6&db=m Decreased prolyl hydroxylase 3 mRNA expression in oncocytomas compared with clear cell renal cell carcinoma. causal interaction,ongoing research,unassigned 3,3,0 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33894356&form=6&db=m The non-canonical functions of HIF prolyl hydroxylases and their dual roles in cancer. unassigned - 1.14.11.29 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34065840&form=6&db=m Gene Expression Levels of the Prolyl Hydroxylase Domain Proteins PHD1 and PHD2 but Not PHD3 Are Decreased in Primary Tumours and Correlate with Poor Prognosis of Patients with Surgically Resected Non-Small-Cell Lung Cancer. diagnostic usage,unassigned 2,0 1.14.11.29 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17726031&form=6&db=m An endoplasmic reticulum transmembrane prolyl 4-hydroxylase is induced by hypoxia and acts on hypoxia-inducible factor alpha. diagnostic usage,ongoing research,unassigned 3,1,0 1.14.11.29 Neurofibromatoses http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26347711&form=6&db=m Pheochromocytomas and Paragangliomas: Clinical and Genetic Approaches. diagnostic usage,unassigned 2,0 1.14.11.29 Non-alcoholic Fatty Liver Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30036883&form=6&db=m Regulatory Role of Endothelial PHD2 in the Hepatic Steatosis. causal interaction,unassigned 1,0 1.14.11.29 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24789921&form=6&db=m HIF Prolyl 4-Hydroxylase-2 Inhibition Improves Glucose and Lipid Metabolism and Protects Against Obesity and Metabolic Dysfunction. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,4 1.14.11.29 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28469071&form=6&db=m Tetrahydrobiopterin activates brown adipose tissue and regulates systemic energy metabolism. ongoing research,therapeutic application,unassigned 4,2,0 1.14.11.29 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30898838&form=6&db=m Genome-Wide Interrogation of Human Cancers Identifies EGLN1 Dependency in Clear Cell Ovarian Cancers. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 1.14.11.29 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21792862&form=6&db=m Prolyl hydroxylase-2 (PHD2) exerts tumor-suppressive activity in pancreatic cancer. diagnostic usage,unassigned 1,0 1.14.11.29 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30555241&form=6&db=m Prolyl hydroxylase domain 3 influences the radiotherapy efficacy of pancreatic cancer cells by targeting hypoxia-inducible factor-1?. causal interaction,ongoing research,unassigned 3,3,0 1.14.11.29 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32905516&form=6&db=m Overexpression of hydroxyproline via EGLN/HIF1A is associated with distant metastasis in pancreatic cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 1.14.11.29 Paraganglioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26369930&form=6&db=m Modeling dioxygenase enzyme kinetics in familial paraganglioma. ongoing research,therapeutic application,unassigned 2,1,0 1.14.11.29 Paraganglioma, Extra-Adrenal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21933857&form=6&db=m Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia. causal interaction,unassigned 3,0 1.14.11.29 Paraproteinemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19737309&form=6&db=m The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 1.14.11.29 Parkinson Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24040809&form=6&db=m Pharmacological Prolyl Hydroxylase Domain Inhibition as a Therapeutic Target for Parkinson's Disease. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 1.14.11.29 Parkinson Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26818499&form=6&db=m Regulation of ATP13A2 via PHD2-HIF1? Signaling Is Critical for Cellular Iron Homeostasis: Implications for Parkinson's Disease. unassigned - 1.14.11.29 Parkinson Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31685899&form=6&db=m A protective role for N-acylphosphatidylethanolamine phospholipase D in 6-OHDA-induced neurodegeneration. therapeutic application,unassigned 1,0 1.14.11.29 Parkinson Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32377332&form=6&db=m Genetic Analysis of EGLN1 C127S Variant in Taiwanese Parkinson's Disease. unassigned - 1.14.11.29 Peripheral Arterial Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25377872&form=6&db=m Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease. causal interaction,therapeutic application,unassigned 3,4,0 1.14.11.29 Phenylketonurias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7524491&form=6&db=m Molecular characterization of HPH-1: a mouse mutant deficient in GTP cyclohydrolase I activity. unassigned - 1.14.11.29 Phenylketonurias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7542713&form=6&db=m Tetrahydrobiopterin deficiency and brain nitric oxide synthase in the hph1 mouse. causal interaction,ongoing research,unassigned 3,4,0 1.14.11.29 Phenylketonurias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8764604&form=6&db=m Tetrahydrobiopterin and biogenic amine metabolism in the hph-1 mouse. causal interaction,unassigned 1,0 1.14.11.29 Phenylketonurias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8769878&form=6&db=m Neurochemical effects following peripheral administration of tetrahydropterin derivatives to the hph-1 mouse. causal interaction,therapeutic application,unassigned 3,4,0 1.14.11.29 Phenylketonurias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8905183&form=6&db=m Impairment of the nitric oxide/cyclic GMP pathway in cerebellar slices prepared from the hph-1 mouse. ongoing research,unassigned 2,0 1.14.11.29 Phenylketonurias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15144277&form=6&db=m A histological study of the hph-1 mouse mutant: an animal model of phenylketonuria and infantile hypertrophic pyloric stenosis. ongoing research,therapeutic application,unassigned 4,1,0 1.14.11.29 Phenylketonurias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15234340&form=6&db=m Congenic mapping and genotyping of the tetrahydrobiopterin-deficient hph-1 mouse. ongoing research,therapeutic application,unassigned 1,2,0 1.14.11.29 Phenylketonurias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15824200&form=6&db=m Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension. causal interaction,ongoing research,therapeutic application,unassigned 3,2,1,0 1.14.11.29 Phenylketonurias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17242981&form=6&db=m Tetrahydrobiopterin availability, nitric oxide metabolism and glutathione status in the hph-1 mouse; implications for the pathogenesis and treatment of tetrahydrobiopterin deficiency states. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,3,0 1.14.11.29 Phenylketonurias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21550412&form=6&db=m Synthesis and recycling of tetrahydrobiopterin in endothelial function and vascular disease. therapeutic application,unassigned 1,0 1.14.11.29 Phenylketonurias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22241166&form=6&db=m Regulation of ?-adrenergic control of heart rate by GTP-cyclohydrolase 1 (GCH1) and tetrahydrobiopterin. ongoing research,unassigned 2,0 1.14.11.29 Phenylketonurias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25218564&form=6&db=m Anxiety- and depression-like phenotype of hph-1 mice deficient in tetrahydrobiopterin. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 1.14.11.29 Phenylketonurias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28469071&form=6&db=m Tetrahydrobiopterin activates brown adipose tissue and regulates systemic energy metabolism. ongoing research,therapeutic application,unassigned 4,2,0 1.14.11.29 Phenylketonurias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28874201&form=6&db=m Tetrahydrobiopterin (BH4) deficiency is associated with augmented inflammation and microvascular degeneration in the retina. causal interaction,ongoing research,unassigned 1,4,0 1.14.11.29 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19263519&form=6&db=m Manganese (II) induces chemical hypoxia by inhibiting HIF-prolyl hydroxylase: implication in manganese-induced pulmonary inflammation. ongoing research,unassigned 2,0 1.14.11.29 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19284968&form=6&db=m Manganese (II) induces chemical hypoxia by inhibiting HIF-prolyl hydroxylase: Implication in manganese-induced pulmonary inflammation. ongoing research,unassigned 4,0 1.14.11.29 Polycythemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19092153&form=6&db=m PHD2 mutation and congenital erythrocytosis with paraganglioma. causal interaction,unassigned 4,0 1.14.11.29 Polycythemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21933857&form=6&db=m Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia. causal interaction,unassigned 3,0 1.14.11.29 Polycythemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23859443&form=6&db=m Molecular study of congenital erythrocytosis in 70 unrelated patients revealed a potential causal mutation in less than half of the cases (Where is/are the missing gene(s)?). causal interaction,unassigned 3,0 1.14.11.29 Polycythemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24482100&form=6&db=m Hereditary gene mutations in Korean patients with isolated erythrocytosis. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,1,0 1.14.11.29 Polycythemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26624507&form=6&db=m Prolyl-4-Hydroxylase 2 Potentially Contributes to Hepatocellular Carcinoma-Associated Erythrocytosis by Maintaining Hepatocyte Nuclear Factor-4? Expression. causal interaction,unassigned 1,0 1.14.11.29 Polycythemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27292716&form=6&db=m EPAS1 p.M535T mutation in a Bulgarian family with congenital erythrocytosis. causal interaction,unassigned 2,0 1.14.11.29 Polycythemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27325674&form=6&db=m The Zinc Finger of Prolyl Hydroxylase Domain Protein 2 Is Essential for Efficient Hydroxylation of Hypoxia-Inducible Factor ?. causal interaction,therapeutic application,unassigned 1,1,0 1.14.11.29 Polycythemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27821476&form=6&db=m Notch Downregulation and Extramedullary Erythrocytosis in Hypoxia-Inducible Factor Prolyl 4-Hydroxylase 2-Deficient Mice. causal interaction,ongoing research,unassigned 2,1,0 1.14.11.29 Polycythemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28231563&form=6&db=m Hypoxia Pathway Mutations in Pheochromocytomas and Paragangliomas. causal interaction,unassigned 3,0 1.14.11.29 Polycythemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28790514&form=6&db=m The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer. causal interaction,unassigned 4,0 1.14.11.29 Polycythemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29790589&form=6&db=m Genotype-Phenotype Correlation of Hereditary Erythrocytosis Mutations, a single center experience. causal interaction,unassigned 2,0 1.14.11.29 Polycythemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29881576&form=6&db=m Congenital erythrocytosis - discover of a new mutation in the EGLN1 gene. causal interaction,unassigned 2,0 1.14.11.29 Polycythemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30111608&form=6&db=m Loss-of-function zinc finger mutation in the EGLN1 gene associated with erythrocytosis. unassigned - 1.14.11.29 Polycythemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31853455&form=6&db=m An Erythrocytosis-Associated Mutation in the Zinc Finger of PHD2 Provides Insights into Its Binding of p23. causal interaction,unassigned 4,0 1.14.11.29 Polycythemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31980185&form=6&db=m [A new case of rare erythrocytosis due to EGLN1 mutation with review of the literature]. causal interaction,ongoing research,unassigned 4,1,0 1.14.11.29 Polycythemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32755251&form=6&db=m Isolated Erythrocytosis Associated With 3 Novel Missense Mutations in the EGLN1 Gene. causal interaction,ongoing research,therapeutic application,unassigned 4,1,1,0 1.14.11.29 Polycythemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33370224&form=6&db=m Erythrocytosis: genes and pathways involved in disease development. unassigned - 1.14.11.29 Polycythemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34349782&form=6&db=m Identification of Variants Associated With Rare Hematological Disorder Erythrocytosis Using Targeted Next-Generation Sequencing Analysis. causal interaction,diagnostic usage,unassigned 3,3,0 1.14.11.29 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28673571&form=6&db=m High altitude and pre-eclampsia: Adaptation or protection. diagnostic usage,unassigned 3,0 1.14.11.29 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31009679&form=6&db=m Novel association of SNP rs479200 in EGLN1 gene with predisposition to preeclampsia. causal interaction,ongoing research,unassigned 1,1,0 1.14.11.29 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28089830&form=6&db=m Tumor suppressor SPOP ubiquitinates and degrades EglN2 to compromise growth of prostate cancer cells. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 1.14.11.29 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32458625&form=6&db=m Association of EGLN2 rs10680577 Polymorphism with the Risk and Clinicopathological Features of Patients with Prostate Cancer. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,1,0 1.14.11.29 Pulmonary Arterial Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27596558&form=6&db=m [Correlation between EGLN1 gene, protein express in lung tissue of rats and pulmonary artery pressure at different altitude]. diagnostic usage,ongoing research,unassigned 4,3,0 1.14.11.29 Pulmonary Disease, Chronic Obstructive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23936167&form=6&db=m Refining susceptibility loci of chronic obstructive pulmonary disease with lung eqtls. ongoing research,unassigned 1,0 1.14.11.29 Pulmonary Disease, Chronic Obstructive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24045616&form=6&db=m Variants in two adjacent genes, EGLN2 and CYP2A6, influence smoking behavior related to disease risk via different mechanisms. causal interaction,unassigned 2,0 1.14.11.29 Pulmonary Disease, Chronic Obstructive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24498427&form=6&db=m Smoking dysregulates the human airway basal cell transcriptome at COPD risk locus 19q13.2. therapeutic application,unassigned 1,0 1.14.11.29 Pulmonary Disease, Chronic Obstructive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25609945&form=6&db=m EGLN2 and RNF150 genetic variants are associated with chronic obstructive pulmonary disease risk in the Chinese population. causal interaction,diagnostic usage,unassigned 3,1,0 1.14.11.29 Pulmonary Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20956315&form=6&db=m EGLN1 involvement in high-altitude adaptation revealed through genetic analysis of extreme constitution types defined in Ayurveda. causal interaction,diagnostic usage,unassigned 4,2,0 1.14.11.29 Pulmonary Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27210110&form=6&db=m Raised HIF1? during normoxia in high altitude pulmonary edema susceptible non-mountaineers. causal interaction,unassigned 3,0 1.14.11.29 Pyloric Stenosis, Hypertrophic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15144277&form=6&db=m A histological study of the hph-1 mouse mutant: an animal model of phenylketonuria and infantile hypertrophic pyloric stenosis. ongoing research,therapeutic application,unassigned 4,1,0 1.14.11.29 Pyloric Stenosis, Hypertrophic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25359537&form=6&db=m Infantile hypertrophic pyloric stenosis (IHPS): a study of its pathophysiology utilizing the newborn hph-1 mouse model of the disease. ongoing research,unassigned 2,0 1.14.11.29 Renal Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21406036&form=6&db=m HIF prolyl hydroxylase inhibitors for anemia. causal interaction,therapeutic application,unassigned 4,4,0 1.14.11.29 Renal Insufficiency, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28483447&form=6&db=m Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies. causal interaction,therapeutic application,unassigned 4,4,0 1.14.11.29 Renal Insufficiency, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28651951&form=6&db=m Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease. causal interaction,therapeutic application,unassigned 4,4,0 1.14.11.29 Renal Insufficiency, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30952940&form=6&db=m Inhibition of prolyl hydroxylase domain (PHD) by JTZ-951 reduces obesity-related diseases in the liver, white adipose tissue, and kidney in mice with a high-fat diet. causal interaction,therapeutic application,unassigned 3,4,0 1.14.11.29 Renal Insufficiency, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31908020&form=6&db=m HIF hydroxylase inhibitors decrease cellular oxygen consumption depending on their selectivity. causal interaction,therapeutic application,unassigned 4,4,0 1.14.11.29 Renal Insufficiency, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32476498&form=6&db=m Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease? causal interaction,therapeutic application,unassigned 3,4,0 1.14.11.29 Renal Insufficiency, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34497234&form=6&db=m [Future perspectives of treatment for anemia in chronic kidney disease (CKD) using hypoxia-inducible factor prolyl hydroxylase inhibitors]. therapeutic application,unassigned 4,0 1.14.11.29 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31908020&form=6&db=m HIF hydroxylase inhibitors decrease cellular oxygen consumption depending on their selectivity. causal interaction,therapeutic application,unassigned 4,4,0 1.14.11.29 Sarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16161047&form=6&db=m Induction of human endometrial cancer cell senescence through modulation of HIF-1alpha activity by EGLN1. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 1.14.11.29 Spinal Cord Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33819286&form=6&db=m Hypoxia-inducible factor prolyl hydroxylase domain (PHD) inhibition after contusive spinal cord injury does not improve locomotor recovery. unassigned - 1.14.11.29 Stomach Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22236543&form=6&db=m Prolyl hydroxylase domain 2 protein is a strong prognostic marker in human gastric cancer. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,2,0 1.14.11.29 Stomach Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22290580&form=6&db=m Overexpression of the HIF hydroxylase PHD3 is a favorable prognosticator for gastric cancer. unassigned - 1.14.11.29 Stomach Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24517638&form=6&db=m An Insertion/Deletion Polymorphism Within the Proximal Promoter of EGLN2 Is Associated With Susceptibility for Gastric Cancer in the Chinese Population. diagnostic usage,unassigned 1,0 1.14.11.29 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16227210&form=6&db=m Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 1.14.11.29 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21406036&form=6&db=m HIF prolyl hydroxylase inhibitors for anemia. causal interaction,therapeutic application,unassigned 4,4,0 1.14.11.29 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20930171&form=6&db=m Hypoxia and Upregulation of Hypoxia-Inducible Factor 1{alpha} Stimulate Venous Thrombus Recanalization. ongoing research,unassigned 2,0 1.14.11.29 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30031289&form=6&db=m Inhibition of prolyl hydroxylase domain proteins selectively enhances venous thrombus neovascularisation. causal interaction,therapeutic application,unassigned 2,2,0 1.14.11.29 Triple Negative Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28036276&form=6&db=m EglN2 contributes to triple negative breast tumorigenesis by functioning as a substrate for the FBW7 tumor suppressor. ongoing research,therapeutic application,unassigned 4,1,0 1.14.11.29 Triple Negative Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31729379&form=6&db=m Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer. unassigned - 1.14.11.29 Uterine Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16161047&form=6&db=m Induction of human endometrial cancer cell senescence through modulation of HIF-1alpha activity by EGLN1. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 1.14.11.29 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15774769&form=6&db=m Tetrahydrobiopterin deficiency exaggerates intimal hyperplasia after vascular injury. causal interaction,unassigned 3,0 1.14.11.29 Ventricular Dysfunction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20410830&form=6&db=m Chronic Inhibition of Hypoxia-Inducible Factor (HIF) Prolyl 4-Hydroxylase Improves Ventricular Performance, Remodeling and Vascularity Following Myocardial Infarction in the Rat. causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0